Navigation Links
American Brain Tumor Association-Funded Research Spurs Development of New Treatments

Chicago, IL (PRWEB) November 21, 2013

In just three years since the American Brain Tumor Association (ABTA) launched its Discovery Grant program, the organization is pleased to announce that its funding has aided the development of two new brain tumor drugs that target malignant gliomas such as glioblastoma multiforme (GBM)—a common and aggressive type of malignant brain tumor.

While meeting with leading scientists and neuro-oncologists this week at the Society for Neuro-Oncology’s Annual Conference in San Francisco, Calif., ABTA President and CEO Elizabeth M. Wilson is optimistic about the interest shown in taking innovative approaches to the treatment of brain tumors.

“Most encouraging to us is that these drugs work differently than existing therapies,” said Wilson “They represent entirely new treatment approaches and they show real progress and hold real hope for brain tumor treatment breakthroughs.”

Still in the very early phases of development and years away from human testing, these results reflect the intended goal of the ABTA Discovery Grant program to bring new drugs to the testing stage and build a promising pipeline of therapies for further research.

One of the drugs has been selected for follow-on funding by a venture capital firm, the other has given rise to a new biopharmaceutical company.

Starving Cancer Cells of Energy
David S. Baskin, M.D., and Martyn A. Sharpe, Ph.D., Department of Neurosurgery at the Houston Methodist Hospital and Dallas-based Remeditex Ventures LLC, have entered into an agreement to develop one of these new drugs, called MP-MUS. Shown to kill human GBM in cell culture, MP-MUS is now being tested against GBM in a mouse brain model. The drug is designed to be converted into a highly toxic form by a specific enzyme which is only highly expressed in GBM. The active form of the drug attacks the cancer cell’s powerhouse—mitochondria. Damaged mitochondria starve the cancer cells of energy, eventually killing the GBM cells.

OLIG2 Inhibitors
Another ABTA-funded study, being conducted by Rajesh Mukthavaram, Ph.D. in the lab of Santosh Kesari, M.D., Ph.D., is advancing research into small molecule inhibitors that target a protein called OLIG2. This protein– which is not active in normal brain tissue–plays an important role because large amounts of OLIG2 are found in almost all gliomas, including GBM. The abundance of this protein drives tumor growth and promotes resistance to radiation therapy. OLIG2 inhibitors will be given following the conclusion of primary treatment, such as surgery, to complement the conventional therapeutic approach. The OLIG2 technology is licensed to San Diego-based Curtana Pharmaceuticals, of which Kesari is a co-founder.

ABTA Discovery Grants are one-year, $50,000 awards that fund high-impact projects with the potential to change current diagnostic or treatment paradigms for adult and pediatric brain tumor care. The ABTA’s $1.6 million investment in innovative science has grown into $3.2 million in follow-on funds—a testament to discovery science potential to change the way brain tumors are diagnosed or treated. To learn more, visit

Founded in 1973, the American Brain Tumor Association was first and is now the only national organization committed to funding brain tumor research and providing support and education programs for all tumor types and all age groups. For more information, visit

# # #

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Clinical news alert from the American Academy of Orthopaedic Surgeons
2. American College of Cardiology cites new USF Simulation Center for Training Excellence
3. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
4. Young Americans Need to Cut Calorie Intake: Study
5. Hutchinson Center president elected to American Academy of Art and Sciences
6. Can weight loss help African-American breast cancer survivors?
7. Americans Support Medicare Reform, But Not on Their Dime: Poll
8. One-third of adult Americans with arthritis battle anxiety or depression
9. Equal access to care helps close survival gap for young African-American cancer patients
10. Systemic sclerosis complications more severe in African Americans than Caucasians
11. 53 million Americans might have diabetes by 2025, according to a new study in Population Health Management
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ChiliPad , ... to maximize recovery through quality sleep. Tim DiFrancesco, training coach for the LA ... night’s sleep. ChiliPad precisely regulates the surface temperature of each side of the ...
(Date:11/30/2015)... ... 2015 , ... Using a combination of two blood sugar tests rather than ... to a new study by researchers at the School of Public Health at Georgia ... Combinations of Blood Glucose Tests ,” published in Frontiers in Public Health, the researchers ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed and approved “NJ Top Dentist”, ... Tufts School of Dental Medicine in 1935. His father graduated from NYU School ... in dentistry as well as their commitment and passion to the Practice of Dentistry. ...
(Date:11/30/2015)... New York, NY (PRWEB) , ... November 30, 2015 , ... ... New York Times,” will be released on December 1, 2015, to coincide with World ... book about the groundbreaking journalist who covered the AIDS epidemic as he was dying ...
(Date:11/30/2015)... ... November 30, 2015 , ... The American Society for Clinical ... of World AIDS Day 2015. On Nov. 30, ASCP shared its “Give a minute. ... World AIDS Day and the importance of getting tested for HIV. , ASCP has ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... November 30, 2015 North America ... expected to grow at a CAGR of 7.6% from 2015 to ... at USD 135.6 million in 2014, and is expected to grow ... According to the new Market Research Report "North America Cardiac ... End User (Hospitals, ambulatory care, others) - Analysis And Forecast To ...
(Date:11/30/2015)...  Kevin Smith has been appointed Chief Commercial ... in wireless monitoring of vital signs.  As CCO ... Mr. Smith will be responsible for the development ... will also directly oversee partnering with US hospitals ... SensiumVitals, the first early warning detection device to ...
(Date:11/30/2015)... SAN DIEGO , Nov. 30, 2015 ... ) today announced that the U.S. Food and Drug ... Application (NDA) for an extended release formulation of lorcaserin. ... a chronic weight management treatment in a once-daily dosing ... as an adjunct to a reduced-calorie diet and increased ...
Breaking Medicine Technology: